Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4724 ARTÍCULOS , VIENDO DEL 631 AL 645

The Roles of Age and Aging in Essential Tremor: An Epidemiological Perspective

Louis ED.

Neuroepidemiology. 2019;52(1-2):111-118. doi: 10.1159/000492831. Epub 2019 Jan 9.

Cross-sectional comparison of spiral versus block integrated curriculums in preparing medical students to diagnose and manage concussions

Fraser S, Wright AD, van Donkelaar P, Smirl JD.

BMC Med Educ. 2019 Jan 9;19(1):17. doi: 10.1186/s12909-018-1439-0.

Editorial: We may need large trials to find treatments for neurodegenerative diseases

Schoenfeld DA, Benatar M.

Clin Trials. 2019 Apr;16(2):120-121. doi: 10.1177/1740774518820814. Epub 2019 Jan 10.

Why would Parkinson's disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses

Lauring JO, Ishizu T, Kutlikova HH, Dörflinger F, Haugbøl S, Leder H, Kupers R, Pelowski M.

Neurosci Biobehav Rev. 2019 May;100:129-165. doi: 10.1016/j.neubiorev.2018.12.016. Epub 2019 Jan 8.

Impact of infection on risk of Parkinson's disease: a quantitative assessment of case-control and cohort studies

Meng L, Shen L, Ji HF.

J Neurovirol. 2019 Apr;25(2):221-228. doi: 10.1007/s13365-018-0707-4. Epub 2019 Jan 10.

Research and development of anti-Parkinson's drugs: an analysis from the perspective of technology flows measured by patent citations

Qu J, Lu J, Hu Y.

Expert Opin Ther Pat. 2019 Feb;29(2):127-135. doi: 10.1080/13543776.2019.1567712. Epub 2019 Jan 19.

The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration

Mor DE, Daniels MJ, Ischiropoulos H.

Mov Disord. 2019 Feb;34(2):167-179. doi: 10.1002/mds.27607. Epub 2019 Jan 11.

What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases

Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele MC.

Microorganisms. 2019 Jan 10;7(1):14. doi: 10.3390/microorganisms7010014.

Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease

Shao Y, Le W.

Mol Neurodegener. 2019 Jan 11;14(1):3. doi: 10.1186/s13024-018-0304-2.

Tau PET imaging in neurodegenerative tauopathies-still a challenge

Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, Nordberg A.

Mol Psychiatry. 2019 Aug;24(8):1112-1134. doi: 10.1038/s41380-018-0342-8. Epub 2019 Jan 11.

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease

Hattori N, Takeda A, Takeda S, Nishimura A, Nakaya R, Mochizuki H, Nagai M, Takahashi R.

J Neural Transm (Vienna). 2019 Mar;126(3):289-297. doi: 10.1007/s00702-018-1962-5. Epub 2019 Jan 11.

Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson's disease and its treatment

Borroto-Escuela DO, Fuxe K.

J Neural Transm (Vienna). 2019 Apr;126(4):455-471. doi: 10.1007/s00702-019-01969-2. Epub 2019 Jan 14.

CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD

Liguori C, Paoletti FP, Placidi F, Ruffini R, Sancesario GM, Eusebi P, Mercuri NB, Parnetti L.

Curr Neurol Neurosci Rep. 2019 Jan 14;19(2):3. doi: 10.1007/s11910-019-0918-y.

α-Synuclein and Glia in Parkinson's Disease: A Beneficial or a Detrimental Duet for the Endo-Lysosomal System?

Filippini A, Gennarelli M, Russo I.

Cell Mol Neurobiol. 2019 Mar;39(2):161-168. doi: 10.1007/s10571-019-00649-9. Epub 2019 Jan 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias